The role of interferons in ovarian cancer progression: Hinderer or promoter?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of interferons in ovarian cancer progression: Hinderer or promoter?
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-12-21
DOI
10.3389/fimmu.2022.1087620
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
- (2022) Chen Liu et al. Frontiers in Immunology
- Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
- (2022) Yash Agarwal et al. Nature Biomedical Engineering
- The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines
- (2022) Justyna Borucka et al. BIOMEDICINE & PHARMACOTHERAPY
- Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity
- (2022) Nishant Chovatiya et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Type I interferon-mediated tumor immunity and its role in immunotherapy
- (2022) Renren Yu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Interferon‐γ Induced PD‐L1 Expression in Ovarian Cancer Cells is Regulated by IRF1 Signaling
- (2022) Sveta Padmanabhan et al. FASEB JOURNAL
- Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer
- (2022) Chang-Suk Chae et al. Cancer Discovery
- Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations
- (2022) Mitchell Acland et al. Cancers
- The global burden and associated factors of ovarian cancer in 1990–2019: findings from the Global Burden of Disease Study 2019
- (2022) Shiwen Zhang et al. BMC PUBLIC HEALTH
- Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients
- (2022) Jing Liu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy
- (2022) Yueyi Li et al. Frontiers in Immunology
- IFN-γ/Doxorubicin Complex Nanoparticles for Enhancing Therapy in the Context of Human Ovarian Carcinoma
- (2022) Rongyuan Yi et al. Frontiers in Materials
- Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”
- (2022) Kaoru Abiko et al. BRITISH JOURNAL OF CANCER
- IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling
- (2022) Sveta Padmanabhan et al. CELLULAR SIGNALLING
- Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
- (2022) Daniel S. Green et al. CLINICAL CANCER RESEARCH
- Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
- (2022) Emi A. Lutz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response
- (2022) Meike Schmitt et al. Cancers
- Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
- (2021) Tan-Trieu Nguyen et al. CLINICAL CANCER RESEARCH
- Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment
- (2021) Vera M. Kho et al. CELLULAR IMMUNOLOGY
- ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell‐like features in cisplatin‐resistant ovarian cancer
- (2021) Qi Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2021) Usha Menon et al. LANCET
- Radiotherapy: An immune response modifier for immuno-oncology
- (2021) Mara De Martino et al. SEMINARS IN IMMUNOLOGY
- Induction of Cell Death in Ovarian Cancer Cells by Doxorubicin and Oncolytic Vaccinia Virus is Associated with CREB3L1 Activation
- (2021) Anna Mistarz et al. Molecular Therapy-Oncolytics
- A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
- (2021) Morgane Boulch et al. Science Immunology
- Activating a collaborative innate-adaptive immune response to control metastasis
- (2021) Lijuan Sun et al. CANCER CELL
- PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
- (2021) Joseph M. Gozgit et al. CANCER CELL
- Epigenetic therapies in ovarian cancer alter repetitive element expression in a TP53-dependent manner
- (2021) James I. McDonald et al. CANCER RESEARCH
- IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway
- (2021) A. H. Gao et al. Clinical & Translational Oncology
- IFN-α, IFN-γ, IL-2 combined with TNF-α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.
- (2021) Penghui Xing et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
- (2021) Gerald Steven Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function
- (2021) Xiang Li et al. JOURNAL OF CONTROLLED RELEASE
- Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
- (2021) Fernanda G Herrera et al. Cancer Discovery
- Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
- (2021) Marine Bruand et al. Cell Reports
- Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers
- (2021) Ying Ni et al. Immunotherapy
- IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration
- (2021) Sveta Padmanabhan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration
- (2021) K. He et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Mitochondrial translation is required for sustained killing by cytotoxic T cells
- (2021) Miriam Lisci et al. SCIENCE
- CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
- (2021) Robert Cornelison et al. Cancers
- PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer
- (2021) Antons Martincuks et al. Frontiers in Oncology
- NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44
- (2021) Rüdiger Klapdor et al. Biomedicines
- Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus
- (2020) Tiphaine Delaunay et al. Journal of Thoracic Oncology
- Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?
- (2020) Vildan B. Cetintas et al. Journal of Translational Medicine
- Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
- (2020) Sara Moufarrij et al. Scientific Reports
- Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
- (2020) João Manuel Santos et al. Journal for ImmunoTherapy of Cancer
- Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells
- (2020) Grazia Carbotti et al. Cancers
- IL-10 suppresses IFN-γ-mediated signaling in lung adenocarcinoma
- (2020) Yi Gao et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Interferon‐γ Induces PD‐L1 Expression in Ovarian Cancer Cells by JAK/STAT1 Signaling
- (2020) Sveta Padmanabhan et al. FASEB JOURNAL
- Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
- (2020) Ilaria Betella et al. GYNECOLOGIC ONCOLOGY
- The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling
- (2020) Eslam Mohamed et al. IMMUNITY
- Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner
- (2020) Pei-Ming Yang et al. Biomolecules
- Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
- (2020) Tong Li et al. BMC CANCER
- Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer
- (2020) Jiawen Zhang et al. CELL DEATH AND DIFFERENTIATION
- Old dogs, new trick: classic cancer therapies activate cGAS
- (2020) Seoyun Yum et al. CELL RESEARCH
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
- (2020) Raffaella Soldi et al. PLoS One
- Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins
- (2020) Emelie Foord et al. Journal of Immunology Research
- RIG-I-like receptor LGP2 is required for tumor control by radiation therapy
- (2020) Wenxin Zheng et al. CANCER RESEARCH
- Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency
- (2020) Parinaz Mehdipour et al. NATURE
- P06.10 Short term inhibition of checkpoint proteins increases ex vivo expansion of tumour infiltrating lymphocytes in high grade serous ovarian cancer
- (2020) CA Waddell et al. Journal for ImmunoTherapy of Cancer
- Tumor Extracellular Vesicles Impede Interferon Alert Responses
- (2019) Candia M. Kenific et al. CANCER CELL
- Interferon‐regulated suprabasin is essential for stress‐induced stem‐like cell conversion and therapy resistance of human malignancies
- (2019) Sona Hubackova et al. Molecular Oncology
- Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use
- (2019) Daniel S. Green et al. Journal of Translational Medicine
- Dual blockade of CXCL12-CXCR4 and PD-1–PD-L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment
- (2019) Yang Zeng et al. FASEB JOURNAL
- Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression
- (2019) Tamaki Yahata et al. CANCER SCIENCE
- Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer
- (2019) Daniel S Green et al. Immunotherapy
- Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment
- (2019) Xian Chen et al. Journal of Translational Medicine
- Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses
- (2019) Philipp Schuster et al. Cancers
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- Rational combinations of immunotherapy with radiotherapy in ovarian cancer
- (2019) Fernanda G Herrera et al. LANCET ONCOLOGY
- Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1
- (2019) Jing-Jing Wang et al. OncoImmunology
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
- (2019) Xi Chen et al. Acta Pharmaceutica Sinica B
- 1876PDImmunogenicity of BRCA1-deficient ovarian cancers is driven through DNA sensing and is augmented by PARP inhibition
- (2019) M Bruand et al. ANNALS OF ONCOLOGY
- The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors
- (2019) Changwen Deng et al. MOLECULAR THERAPY
- Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer
- (2018) Gemma L. Owens et al. JOURNAL OF IMMUNOTHERAPY
- A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
- (2018) Daniel S. Green et al. Journal of Translational Medicine
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
- (2018) Janos L. Tanyi et al. Science Translational Medicine
- Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses
- (2018) Gautam N. Shenoy et al. Cancer Immunology Research
- Novel therapeutic strategies for advanced ovarian cancer by using iPS cell-derived myelomonocytic cells producing interferon beta
- (2018) Yuko Imamura et al. CANCER SCIENCE
- The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells
- (2018) Yue Zou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
- (2018) Olga V. Matveeva et al. REVIEWS IN MEDICAL VIROLOGY
- Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
- (2018) Can Liu et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs
- (2018) Enguang Bi et al. JOURNAL OF CLINICAL INVESTIGATION
- Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
- (2018) Nina Marí Gual Pimenta de Queiroz et al. MOLECULAR CANCER RESEARCH
- IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
- (2018) Minkyung Song et al. NATURE
- Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
- (2018) Wouter Scheper et al. NATURE MEDICINE
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
- (2018) Emelie Rådestad et al. OncoImmunology
- Mathematical modeling of the cGAS pathway reveals robustness of DNA sensing to TREX1 feedback
- (2018) Robert W. Gregg et al. JOURNAL OF THEORETICAL BIOLOGY
- Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells
- (2017) Ali Razaghi et al. EXPERIMENTAL CELL RESEARCH
- IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
- (2017) M. Felices et al. GYNECOLOGIC ONCOLOGY
- Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy
- (2017) Rüdiger Klapdor et al. HUMAN GENE THERAPY
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts
- (2017) Yujuan Li et al. Frontiers in Immunology
- Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
- (2016) T. K. Eigentler et al. ANNALS OF ONCOLOGY
- Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins
- (2016) Heidi Gytz et al. BIOLOGY OF THE CELL
- Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
- (2016) Weimin Wang et al. CELL
- A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN versus IFN in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
- (2016) R. E. Hawkins et al. CLINICAL CANCER RESEARCH
- A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer
- (2016) Isabella Monia Montagner et al. JOURNAL OF CONTROLLED RELEASE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
- (2016) Catherine Dold et al. Molecular Therapy-Oncolytics
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
- (2015) Peter Mohr et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon alpha-inducible protein 27 promotes epithelial–mesenchymal transition and induces ovarian tumorigenicity and stemness
- (2015) Shuqin Li et al. JOURNAL OF SURGICAL RESEARCH
- Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients
- (2015) Xin Wei et al. TUMOR BIOLOGY
- B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
- (2015) Silvia Pesce et al. OncoImmunology
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Radiation-Induced IFN- Production within the Tumor Microenvironment Influences Antitumor Immunity
- (2014) A. A. Lugade et al. JOURNAL OF IMMUNOLOGY
- CpG ODN Nanorings Induce IFN from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity
- (2014) B. Gungor et al. Science Translational Medicine
- ISG12a mediates cell response to Newcastle disease viral infection
- (2014) Nianli Liu et al. VIROLOGY
- IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
- (2013) Scott A. Gerber et al. AMERICAN JOURNAL OF PATHOLOGY
- Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer
- (2011) Mark J. Dobrzanski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monocyte-derived DC maturation strategies and related pathways: a transcriptional view
- (2011) Luciano Castiello et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer
- (2011) S. I. Labidi-Galy et al. CANCER RESEARCH
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma
- (2010) Yun-Sook Kim et al. BMC CANCER
- Unknown
- (2010) Karoline Lipnik et al. MOLECULAR MEDICINE
- p21WAF1 is involved in interferon-β- induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression in ovarian cancer
- (2010) Ji-Hae Lee et al. MOLECULES AND CELLS
- Multiple roles for CD4+T cells in anti-tumor immune responses
- (2008) Richard Kennedy et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now